Celularity Inc. (CELU) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Celularity Inc. is a regenerative and cellular medicines company focused on aging-related diseases, operating through three segments: Cell Therapy, Degenerative Disease (biomaterials), and BioBanking. The company has no approved cellular therapeutic candidates and relies on revenues from biomaterials and biobanking services alongside external financing.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Total Net Revenues | $5.3 million | $9.3 million | $22.4 million | $36.1 million |
| Net Loss | $(23.1) million | $(16.1) million | $(67.4) million | $(44.6) million |
| Loss Per Share (Basic/Diluted) | $(0.88) | $(0.73) | $(2.74) | $(2.05) |
| Cash and Cash Equivalents | $0.12 million | $0.74 million | $0.12 million | $0.74 million |
| Total Debt (Short-term) | $4.3 million | $6.4 million | $4.3 million | $6.4 million |
| Accumulated Deficit | $(967.1) million | $(886.4) million | $(967.1) million | $(886.4) million |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 43.2% in Q3 and 37.8% YTD compared to the prior year. This was primarily driven by a significant drop in product sales (down 73.7% in Q3) due to lower sales of Biovance 3L and Rebound products.
- Cost of Revenues Increase: Despite lower revenue, cost of revenues increased 204.6% in Q3 and 66.1% YTD. This counter-intuitive trend was caused by a $1.4 million write-off of capitalized bulk material costs in Q3 and $3.9 million YTD, alongside $2.4 million in milestone payments for the Rebound acquisition.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses decreased 26.4% in Q3 and 15.0% YTD, reflecting cost-cutting measures including reduced commission and facility expenses. R&D expenses increased 17.4% in Q3 but decreased 13.9% YTD.
- Other Expenses: Total other expenses surged due to non-cash items, including a $2.3 million loss on the issuance of a convertible note with warrants and a $5.3 million loss on the change in fair value of warrant liabilities YTD.
- Debt Restructuring: The company settled significant related-party debt (C.V. Starr and RWI loans) in Q3 by assigning obligations to Celeniv Pte. Ltd. in exchange for intellectual property, resulting in a new licensing obligation of approximately $35.7 million.
Guidance, Outlook, and Risks
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern. As of the issuance date, the company had insufficient unrestricted cash ($0.12 million) to fund operations for the next 12 months and no secured capital to sustain operations.
- Liquidity Strategy: The company is actively seeking additional capital through equity offerings, debt financings, or strategic alternatives. Failure to secure funding may force the company to curtail operations, liquidate assets, or seek bankruptcy protection.
- Recent Financing: In October 2025 (subsequent to the period end), the company closed the initial tranche of a private placement for approximately $2.0 million in gross proceeds via Series A Convertible Preferred Stock.
- Operational Risks: Key risks include the inability to obtain regulatory approval for therapeutic candidates, reliance on distribution partners for biomaterials sales, and ongoing legal proceedings (including a Civil Investigative Demand under the False Claims Act and various contract disputes).
- Internal Controls: The company disclosed that its disclosure controls and procedures were not effective due to material weaknesses in internal control over financial reporting, including failures in the control environment, risk assessment, and monitoring.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $2.0 million raised in the October 2025 private placement against the company's burn rate and the $35.7 million new licensing obligation.
- Revenue Quality: Assess the sustainability of the Degenerative Disease segment given the sharp decline in Biovance 3L sales and the impact of the Rebound acquisition milestone payments on margins.
- Debt Obligations: Review the terms of the new licensing obligation with Celeniv and the remaining related-party debt to understand future cash outflow requirements.
- Legal Exposure: Monitor the status of the False Claims Act investigation and pending judgments from TCWGlobal and Clinical Resource Network.
- Internal Controls: Evaluate the progress of the remediation plan for material weaknesses in internal controls, which previously led to late filings.